Clinical trials represent a cornerstone of modern clinical research, systematically investigating the safety, efficacy and overall impact of medical interventions. Equally important is the ...

GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study; Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits ...

Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits for the NHS-Galleri Trial; Final Results Expected in 2026 PATHFINDER 2 is a ...

LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (OKYO) (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat ...

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary ...

When Malcolm MacLeod made it his personal mission to update the results of every clinical trial ever registered at the University of Edinburgh, UK, he didn’t realize that the effort would take years.

KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech ...

Registering your study with ClinicalTrials.gov is a necessary step for investigators to be compliant with regulations. This UB CTSI Educational Modules video provides useful insights to the Protocol ...

NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders ...

RE104 is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, which is administered via a single subcutaneous injection. Reunion designed RE104 to deliver a short, acute psychoactive ...

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...